Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history

SÁNCHEZ-LUCEROS A; MESCHENGIESER SS; TURDÓ K; ARIZO A; WOODS AI; CASAIS P; BLANCO AN; KEMPFER AC; LAZZARI MA

THROMBOSIS RESEARCH

Pergamon Press

Lugar: USA; Año: 2006

0049-3848

We reviewed the records of 54 women with a low plasmatic VWF level and bleeding history, who had used desmopressin during pregnancy. No adverse effects were observed in mothers or newborns, including those exposed to the drug during the first trimester. No local complication of epidural placement was observed. DDAVP merits to be considered as the first choice of therapy, when patients with a previous or current low plasmatic VWF level present bleeding complications, including pregnant women. Although post-partum bleeding will appear in a small proportion of VWD women, there is no accurate way to identify who is going to bleed. The use of DDAVP should be regarded as a highly valuable option.